Physician profile
George L Morris
NPI 1295778629
$13,792.48
in general payments reported to CMS, 2019-2025
15 companies · $2,443 in 2025
The $2,443 reported for 2025 was more than what 79% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,675 · 2020: $826 · 2021: $3,245 · 2022: $247 · 2023: $3,166 · 2024: $191 · 2025: $2,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,415 · Food and Beverage: $368 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,415.00 |
| Food and Beverage | $368.09 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $6,961.65 | 2019-2022 | |
| Ucb, INC. | $5,354.76 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Allergan, INC. | $340.00 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $315.00 | 2025 | |
| Greenwich Biosciences, INC. | $215.35 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $186.28 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $111.69 | 2019-2021 | |
| Catalyst Pharmaceuticals, INC. | $101.80 | 2023-2025 | Fycompa |
| Eisai INC. | $79.18 | 2019-2021 | |
| Sk Life Science, INC. | $45.33 | 2020-2022 | |
| Neuropace, INC. | $31.68 | 2021 | |
| Aucta Pharmaceuticals, INC. | $25.20 | 2024 | Motpoly Xr |
| Sunovion Pharmaceuticals INC. | $13.16 | 2019 | |
| Neurelis, INC. | $11.40 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.